Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signatureIeuan Walker, Michael A. Chapman, Kane Foster et al.|medRxiv|2023Cited by 2
OAB-018: From CARDAMON to CoMMpass: a mutational signature that predicts carfilzomib-specific outcomes in myelomaIeuan Walker, Michael Chapman, Garima Khandelwal et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 0
Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in MyelomaIeuan Walker, Michael A. Chapman, Venetia D’arcy et al.|Blood|2022Cited by 0
High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple MyelomaIeuan Walker, Michael A. Chapman, Venetia D’arcy et al.|Blood|2023Cited by 0